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Treatment-free remission (TFR) is a new therapy-goal for persons with chronic 
phase chronic myeloid leukemia (CML) receiving tyrosine kinase-inhibitors (TKIs), 
with approximately 40% sustaining deep molecular responses after stopping 
treatment (1-3). However, predicting who will achieve TFR is imprecise and 
controversial (3). We report data from 64 persons who stopped TKI-therapy and 
showed a significant association between the type of BCR-ABL1 transcript and age 
on the probability of TFR. 
 
Subjects were in 1st chronic phase and had a deep molecular response (≥MR4 on 
International Scale) for ≥1 year before stopping TKI-therapy, equivalent to the 
eligibility criteria of the Euro-Ski trial (4). Molecular response level was calculated by 
standard criteria (5) and molecular relapse defined as loss of MR3. Time to 
molecular relapse was measured from the date of TKI-discontinuation to the first of 
≥2 consecutive quantitative real-time polymerase chain reaction (qRT-PCR) 
assessments confirming <MR3. 
  
TFR was defined as the interval between the date of stopping TKI-therapy and date 
of molecular relapse or, if this did not happen, the date of last contact. Continuous 
variables were dichotomized to assess prognostic values for TFR using the median 
value. Sensitivity analysis was done for these variables excluding outlier values.  For 
the age we interrogated cut-points at the median (51 years) and at ages 40 and 60 
years. P-values <0.05 (two-tailed) were considered significant. Potential predictive 
variables for TFR were analysed in univariate analyses by the Kaplan-Meier method. 
Only the statistically significant variables were included in multivariate analyses 
using a Cox proportional hazard regression model. 
 
Subject, disease and therapy related variables before stopping TKI-therapy are 
displayed in Table 1. Median follow-up from stopping TKI-therapy was 26 months 
(range, 6-121 months). Forty-one subjects (64%; [95% confidence interval [CI] 53, 
75%]) stopped TKI because of intolerance, 7 (11%; [5, 19%]) in order to conceive 
and 16 (25%; [14, 36%]) were elected to stop treatment because of the achievement 
of sustained deep response.  At the time of discontinuing TKI 32 subjects (50% [38, 
63%]) were receiving imatinib and 32 (50% [38, 63%), dasatinib or nilotinib. The 
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frequency of patients with e13a2 (42%) or e14a2 transcripts (58%) is similar to that 
reported within the ELN registry at 45% and 55% respectively (8). 
  
Thirty-seven subjects (58% [45, 70%]) remain in molecular remission at a median of 
26 months (range, 7—64 months) after stopping TKI-therapy. The 3-year actuarial 
probability of TFR is 53% (38%, 66%). Twenty-seven subjects (42% [30, 55%]) had 
a molecular relapse at a median of 4 months (range, 1-30 months) after stopping 
TKI-therapy. 
 
In multivariate analysis of factors found to be predictive of TFR in univariate analysis 
(i.e. transcript type, age ≥40, duration of ≥MR4, depth of response and percent TKI 
dose at the time of interruption) only e14a2 transcript type (HR=0.38 [0.18, 0.84], 
p=0.016) and age at diagnosis ≥40 years (HR=0.3 [0.13, 0.66]; p=0.003) remained 
significantly-associated with TFR (Table 2). Figure 1 shows the cumulative incidence 
of losing MR3 for all subjects and those with e13a2 (64% [50, 77%]) and e14a2 
transcripts (35% [15, 56%]). 
 
Twenty-six of 27 subjects with molecular relapse returned to ≥MR3 at a median of 3 
months (range, 1-9 months) after re-starting TKI-therapy. At last follow-up, all were 
alive and in MR3 (5 subjects at 6 months median of follow-up), MR4 (8 subjects at 8 
months median follow-up), or >MR4 (13 subjects at 26 months median follow-up 
after re-starting TKI-therapy). One patient, who stopped TKI in order to conceive, lost 
MR3 at 24 weeks of pregnancy. She restarted TKI 2 months after normal delivery 
and has not yet regained MR3 at 1 month from TKI resumption. 
 
We found that the e14a2 BCR-ABL1 transcript was significantly associated with a 
higher rate of TFR. Several studies interrogated the correlation between BCR-ABL1 
transcript type and response to TKI-therapy, with the e14a2 transcript reported to 
predict increased response to imatinib (6). One recent study showed higher rates of 
MR4.5, better event free- (EFS) and better transformation to blast phase-free 
survival in subjects with an e14a2 transcript compared with those with e13a2, 
regardless of initial TKI-therapy (7); lower response rates for e13a2 were also found 
by other authors (8). Another study in subjects receiving first-line imatinib concluded 
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for absence of impact of different transcript types on overall survival and CML-
related death (9). 
 
The association we report of BCR-ABL1 transcript type and TFR, if confirmed, might 
reflect possible increased tyrosine kinase activity of the e13a2 transcript (6).  
Alternatively, increased immunogenicity of the e14a2 transcript eliciting a stronger 
host immune-mediated anti-CML effect is also described but seems an unlikely 
explanation (10-12).   
 
Age ≥40 years was also associated with a higher likelihood of TFR after stopping 
TKI-therapy. Recent data suggest persons with CML aged 5-29 years have less 
frequent cytogenetic and molecular responses to TKI-therapy compared with older 
persons and an increased risk of transformation to blast phase (13, 14). These data 
are consistent with our findings of an unfavourable impact of age on the probability of 
TFR. Others report a similar association (15). 
 
Our study has important limitations including the retrospective nature, the small 
sample size and a substantial proportion of subjects stopping TKI-therapy because 
of intolerance rather than from a planned stopping strategy. Although our 
conclusions require validation, our data suggest that the presence of e14a2 BCR-
ABL1 transcript type and age ≥40 years at diagnosis improve the probability of TFR. 
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Table 1.  Subject, disease and therapy related variables (N=64). 
 
Sex  
   Males 22 
   Females 42 
Age at diagnosis (y; median, range) 51 (19-87) 
BCR-ABL1 transcript type  
   e14a2 37 
   e13a2 27 
Sokal score at diagnosis   
   Low 23 
   Intermediate 15 
   High 14 
   Unknown 12 
Prior interferon 11 
Interval diagnosis to ≥MR3 (mo; median; range) 7 (2-87) 
Interval diagnosis to ≥MR4 (mo; median; range) 24 (3-108) 
≥MR4 duration* (mo; median; range) 60 (12-156) 
Duration of TKI-therapy (y; median; range) 7 (2-15) 
Reason for stopping TKI   
   Adverse event 41 
   Pregnancy 7 
   Achievement of deep sustained response 16 
Imatinib 1
st
-line at stop  32 
   After optimal response 28 
   After suboptimal response (BCR-ABL IS >10% at 3     
months) 4 
2G-TKI 1
st
-line at stop 13 
2G-TKI 2
nd
-line at stop 14 
   After prior imatinib intolerance 10 
   After prior imatinib failure 4 
2G-TKI 3
rd
-line at stop 5 
    After prior TKI-intolerance 4 
    After prior TKI-resistance 1 
2G-TKI at stop 32 
   Nilotinib 17 
   Dasatinib 15 
TKI-dose at stop (% of standard dose)   
   100% 21 
   75-50 35 
   <50% 7 
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   Missing 1 
 Legend: mo=months; IS=International Scale; TKI= Tyrosine Kinase Inhibitor; 2G-TKI, 2
nd
 generation TKI. 
*corresponding to the interval between the achievement of a sustained BCR-ABL < 0.01% (on International   
Scale) and the date of TKI interruption. 
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Table 2. Univariate and Multivariate Analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
Legend: y=years; mo=months; 2G-TKI= 2
nd
 generation Tyrosine Kinase Inhibitor. 
 
 
 
 
 
 
 
Cumulative incidence of MR3 loss over time (n=64) 
Variable Univariate analysis HR (95% CI); p value 
Multivariate analysis 
HR (95% CI); p value 
BCR-ABL1 transcript e14a2 0.4 (0.18, 0.85); p=0.019 0.38 (0.18, 0.84); p=0.016 
Age at diagnosis ≥40 y 0.31 (0.14, 0.68); p=0.003 0.3 (0.13, 0.66); p=0.003 
Sokal score low+intermediate 0.7 (0.28, 1.72); p=0.44  
Male sex 1.39 (0.63, 3.0); p=0.41  
Prior interferon 0.94 (0.32, 2.72); p=0.91  
TKI therapy >7 y 0.95 (0.45, 2); p=0.9  
Time to achieve MR3 <7 mo 0.71 (0.31, 1.55); p=0.39  
Time to achieve MR4 <24 mo 0.67 (0.38, 1.47); p=0.32  
≥MR4 duration >60 mo 0.37 (0.16, 0.84); p=0.017 0.88 (0.31, 2.5); p=0.824 
Depth of response at stop >MR4 0.38 (0.17, 0.86); p=0.021 0.75 (0.28, 1.97); p=0.56 
2G-TKI at stop 0.61 (0.28, 1.33); p=0.21  
<100% of TKI standard dose at stop  0.45 (0.21, 0.96); p=0.043 0.58 (0.26, 1.32); p=0.19 
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Figure 1. Cumulative incidence of molecular relapse after TKI interruption. 
The figure shows the cumulative incidence of molecular relapse (MR3 loss) after TKI 
interruption for the entire patient cohort (black line, 46% [CI = confidence interval, 31, 
60%] and according to the transcript type (for e13a2, red dashed line, 64% [CI 50, 
77%]; for e14a2, blue dashed line, 35% [CI 15, 56%]). The dotted lines represent 
confidence intervals.  
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